Norfloxacin for the prophylaxis of travelers' diarrhea in U.S. military personnel.
Norfloxacin, an oral fluoroquinolone (dose 400 mg daily), was compared to a placebo in a double blinded randomized trial for the prophylaxis of travelers' diarrhea. The study was of U.S. Navy and Marine Corps personnel on shore leave in Alexandria, Egypt. A total of 222 subjects were available (105 norfloxacin, 117 placebo). In the placebo group, 26% (30/117) developed acute diarrhea vs. 2% (2/105) in the norfloxacin group. There were no significant side effects in either group.
Scott
D A
DA
U.S. Naval Medical Research Unit No. 3, Cairo, Egypt.
Haberberger
R L
RL
Thornton
S A
SA
Hyams
K C
KC
D000208:Acute Disease; D000328:Adult; D003906:Developing Countries; D003967:Diarrhea / Q000517:prevention & control*; D004534:Egypt; D005500:Follow-Up Studies; D006801:Humans; D008889:Military Personnel; D009643:Norfloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D010349:Patient Compliance; D016032:Randomized Controlled Trials as Topic; D012767:Ships; D011795:Surveys and Questionnaires; D014195:Travel; D014481:United States
D009643:Norfloxacin